Proactive Investors - Run By Investors For Investors

Wattle Health Australia eyes Chinese infant formula market

Commencing initial supply of its infant formula to 100 key stores.
Wattle Health Australia eyes Chinese infant formula market
The company listed on the ASX in March 2017

Recently listed Wattle Health Australia (ASX:WHA) has signed an agreement with one of the largest retailers of mother and baby products in China - Aiyingdao Zhuhai Business Chain.

As part of the agreement, Wattle Health will commence initial supply of its infant formula to 100 key stores of Aiyingdao across mainland China.

It is worth noting that Aiyingdao’s network is responsible for 40% of all infant formula sales in China, with over 1000 retail store locations.

The companies are also commencing negotiations to formalise a long-term supply agreement to market infant formula across the entire Aiyingdao network in mainland China.

Based in Melbourne Victoria, Wattle Health is in the business of developing and marketing consumer food products, with an initial focus on dairy products (dried milk and infant formula).

The company listed on the ASX in March 2017 after raising $8 million from an oversubscribed initial public offer.

Interestingly, the company’s shares were last trading at $0.40, double the issue price of $0.20.

Wattle Health uses only Australian manufacturers to manufacture its products.

This is intended to promote and leverage on the brand positively in Australia and in export markets, as there is growing consumer sentiment for Australian made food products.

View full WHA profile View Profile

Wattle Health Australia Ltd Timeline

Related Articles

doctor
June 11 2019
Oncimmune is a specialist in the field of immunodiagnostics
woman's face
Tue
Here we take a closer look at SkinBioTherapeutics, the life sciences group that is using bacteria to improve people’s skin
blood
June 21 2019
Belgium-based company’s Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect ovarian disease endometriosis

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use